1045 related articles for article (PubMed ID: 26017497)
21. Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort.
Bedaiwi M; Sari I; Thavaneswaran A; Ayearst R; Haroon N; Inman RD
J Rheumatol; 2015 Dec; 42(12):2354-60. PubMed ID: 26523020
[TBL] [Abstract][Full Text] [Related]
22. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM; Deodhar A; Akl EA; Lui A; Ermann J; Gensler LS; Smith JA; Borenstein D; Hiratzka J; Weiss PF; Inman RD; Majithia V; Haroon N; Maksymowych WP; Joyce J; Clark BM; Colbert RA; Figgie MP; Hallegua DS; Prete PE; Rosenbaum JT; Stebulis JA; van den Bosch F; Yu DT; Miller AS; Reveille JD; Caplan L
Arthritis Rheumatol; 2016 Feb; 68(2):282-98. PubMed ID: 26401991
[TBL] [Abstract][Full Text] [Related]
23. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
[TBL] [Abstract][Full Text] [Related]
24. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
Haibel H; Sieper J
Curr Opin Rheumatol; 2010 Jul; 22(4):388-92. PubMed ID: 20473176
[TBL] [Abstract][Full Text] [Related]
25. Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Madsen OR
Rheumatol Int; 2018 Mar; 38(3):425-432. PubMed ID: 29299630
[TBL] [Abstract][Full Text] [Related]
26. Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study.
Wang R; Gabriel SE; Ward MM
Arthritis Rheumatol; 2016 Jun; 68(6):1415-21. PubMed ID: 26663907
[TBL] [Abstract][Full Text] [Related]
27. Brief Report: Six-Week Treatment of Axial Spondyloarthritis Patients With an Optimal Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac Joints.
Varkas G; Jans L; Cypers H; Van Praet L; Carron P; Elewaut D; Van den Bosch F
Arthritis Rheumatol; 2016 Mar; 68(3):672-8. PubMed ID: 26473982
[TBL] [Abstract][Full Text] [Related]
28. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.
Deodhar A; Gensler LS; Kay J; Maksymowych WP; Haroon N; Landewé R; Rudwaleit M; Hall S; Bauer L; Hoepken B; de Peyrecave N; Kilgallen B; van der Heijde D
Arthritis Rheumatol; 2019 Jul; 71(7):1101-1111. PubMed ID: 30848558
[TBL] [Abstract][Full Text] [Related]
29. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort.
Tournadre A; Pereira B; Lhoste A; Dubost JJ; Ristori JM; Claudepierre P; Dougados M; Soubrier M
Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1482-9. PubMed ID: 23463610
[TBL] [Abstract][Full Text] [Related]
30. Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.
Protopopov M; Sieper J; Haibel H; Listing J; Rudwaleit M; Poddubnyy D
Arthritis Res Ther; 2017 Oct; 19(1):240. PubMed ID: 29065931
[TBL] [Abstract][Full Text] [Related]
31. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
32. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.
Song IH; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Weiß A; Buß B; Freundlich B; Lange E; Alten R; Rudwaleit M; Sieper J
J Rheumatol; 2014 Oct; 41(10):2034-40. PubMed ID: 25028375
[TBL] [Abstract][Full Text] [Related]
33. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.
Song IH; Weiß A; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Lange E; Freundlich B; Rudwaleit M; Sieper J
Ann Rheum Dis; 2013 Jun; 72(6):823-5. PubMed ID: 23172749
[TBL] [Abstract][Full Text] [Related]
34. The Discriminative Values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Spondyloarthritis-Related Axial Arthritis.
Tsang HHL; Chung HY
J Clin Rheumatol; 2017 Aug; 23(5):267-272. PubMed ID: 28661926
[TBL] [Abstract][Full Text] [Related]
35. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment.
Poddubnyy D; Sieper J
Curr Opin Rheumatol; 2014 Jul; 26(4):377-83. PubMed ID: 24807404
[TBL] [Abstract][Full Text] [Related]
36. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
[TBL] [Abstract][Full Text] [Related]
37. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
[TBL] [Abstract][Full Text] [Related]
38. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM; Deodhar A; Gensler LS; Dubreuil M; Yu D; Khan MA; Haroon N; Borenstein D; Wang R; Biehl A; Fang MA; Louie G; Majithia V; Ng B; Bigham R; Pianin M; Shah AA; Sullivan N; Turgunbaev M; Oristaglio J; Turner A; Maksymowych WP; Caplan L
Arthritis Rheumatol; 2019 Oct; 71(10):1599-1613. PubMed ID: 31436036
[TBL] [Abstract][Full Text] [Related]
39. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases?
Wallis D; Haroon N; Ayearst R; Carty A; Inman RD
J Rheumatol; 2013 Dec; 40(12):2038-41. PubMed ID: 24187102
[TBL] [Abstract][Full Text] [Related]
40. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
